PubMed

Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial.

LaCroix AZ, Ott SM, Ichikawa L, Scholes D, Barlow WE.

Ann Intern Med. 2000 Oct 3;133(7):516-26.PMID: 11015164 [PubMed - indexed for MEDLINE]Related articlesFree article

Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial.

Reid IR, Ames RW, Orr-Walker BJ, Clearwater JM, Horne AM, Evans MC, Murray MA, McNeil AR, Gamble GD.

Am J Med. 2000 Oct 1;109(5):362-70.PMID: 11020392 [PubMed - indexed for MEDLINE]Related articles

Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial.

Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB; Treatment of Osteoporosis with Parathyroid Hormone Study Group.

Ann Intern Med. 2007 Mar 6;146(5):326-39.PMID: 17339618 [PubMed - indexed for MEDLINE]Related articlesFree article

Effectiveness and safety of vitamin D in relation to bone health.

Cranney A, Horsley T, O'Donnell S, Weiler H, Puil L, Ooi D, Atkinson S, Ward L, Moher D, Hanley D, Fang M, Yazdi F, Garritty C, Sampson M, Barrowman N, Tsertsvadze A, Mamaladze V.

Evid Rep Technol Assess (Full Rep). 2007 Aug;(158):1-235. Review.PMID: 18088161 [PubMed - indexed for MEDLINE]Related articles

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M.

N Engl J Med. 1995 Nov 30;333(22):1437-43.PMID: 7477143 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.

Clin Ther. 2007 Sep;29(9):1937-49.PMID: 18035193 [PubMed - indexed for MEDLINE]Related articles

The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial.

Reginster JY, Meurmans L, Zegels B, Rovati LC, Minne HW, Giacovelli G, Taquet AN, Setnikar I, Collette J, Gosset C.

Ann Intern Med. 1998 Jul 1;129(1):1-8.PMID: 9652994 [PubMed - indexed for MEDLINE]Related articlesFree article

Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial.

Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M.

JAMA. 2003 Aug 27;290(8):1042-8.PMID: 12941676 [PubMed - indexed for MEDLINE]Related articlesFree article

The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women.

Bolland MJ, Ames RW, Horne AM, Orr-Walker BJ, Gamble GD, Reid IR.

Osteoporos Int. 2007 Apr;18(4):479-86. Epub 2006 Nov 21.PMID: 17120180 [PubMed - indexed for MEDLINE]Related articles

Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.

Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harper K.

Chin Med J (Engl). 2004 Jul;117(7):1029-35.PMID: 15265377 [PubMed - indexed for MEDLINE]Related articlesFree article

Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.

Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, van de Ven CM, Dijkmans BA.

Osteoporos Int. 2006;17(5):716-23. Epub 2006 Feb 3.PMID: 16463007 [PubMed - indexed for MEDLINE]Related articles

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR.

JAMA. 1999 Aug 18;282(7):637-45. Erratum in: JAMA 1999 Dec 8;282(22):2124. PMID: 10517716 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.

Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR; FLEX Research Group.

JAMA. 2006 Dec 27;296(24):2927-38.PMID: 17190893 [PubMed - indexed for MEDLINE]Related articlesFree article

Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.

Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM; Fracture Intervention Trial Long-Term Extension Research Group.

J Bone Miner Res. 2004 Aug;19(8):1259-69. Epub 2004 Mar 29.PMID: 15231012 [PubMed - indexed for MEDLINE]Related articles

Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.

McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, Kayan K, Beneton M, Jalava T, Pylkkänen L, Kenraali J, Aropuu S, Kanis JA.

J Bone Miner Res. 2004 May;19(5):728-36. Epub 2004 Jan 19.PMID: 15068495 [PubMed - indexed for MEDLINE]Related articles

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.

Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A.

Ann Intern Med. 2002 Dec 3;137(11):875-83.PMID: 12458987 [PubMed - indexed for MEDLINE]Related articlesFree article

Randomized placebo-controlled trial of brisk walking in the prevention of postmenopausal osteoporosis.

Ebrahim S, Thompson PW, Baskaran V, Evans K.

Age Ageing. 1997 Jul;26(4):253-60.PMID: 9271287 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial.

Greenspan SL, Nelson JB, Trump DL, Resnick NM.

Ann Intern Med. 2007 Mar 20;146(6):416-24.PMID: 17371886 [PubMed - indexed for MEDLINE]Related articlesFree article

[Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis]

Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harpe K.

Zhonghua Yi Xue Za Zhi. 2004 Feb 17;84(4):269-73. Chinese. PMID: 15059505 [PubMed - indexed for MEDLINE]Related articles

Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.

McClung MR, Wasnich RD, Recker R, Cauley JA, Chesnut CH 3rd, Ensrud KE, Burdeska A, Mills T; Oral Ibandronate Study Group.

J Bone Miner Res. 2004 Jan;19(1):11-8.PMID: 14753731 [PubMed - indexed for MEDLINE]Related articles